Can a cancer drug help people with HIV pause their daily meds?
NCT ID NCT06660498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether pomalidomide, a drug currently used for multiple myeloma, can help control HIV when people temporarily stop their standard antiretroviral therapy (ART). Thirty-two adults with well-controlled HIV will receive either pomalidomide or a placebo alongside low-dose aspirin. The goal is to see if pomalidomide can delay the need to restart ART by boosting the immune system's ability to suppress the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pomalidomide
What this could lead to
If it works, this could point toward a way for people with HIV to safely stop daily antiretroviral therapy for longer periods.
What could go wrong
This is an early-phase trial with only 32 participants, so results may not apply broadly. Pomalidomide can cause serious side effects, and the treatment interruption carries risks of viral rebound.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Denmark
-
Royal Melbourne Hospital
Melbourne, Australia